Amphastar Pharmaceuticals, Inc., establecida en 1996 y con sede en Rancho Cucamonga, California, funciona como una empresa de biotecnología farmacéutica. La empresa ...
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
BPA est. $0.86 · Ingresos $197.85M · 5 analistas
BPA est. $0.80 · Ingresos $194.74M · 1 analistas
BPA est. $2.97 · Ingresos $747.81M · 3 analistas
BPA est. $0.71 · Ingresos $186.34M · 1 analistas
| Métrica | Último | InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo. | TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo. |
|---|---|---|---|
| IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores). | $719.9M | -1.7% | +7.4% |
| Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día. | $98.1M | -38.5% | +372.7% |
| Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión. | +49.5% | -3.2% | +23.7% |
| Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas). | +19.5% | -30.5% | +171.3% |
| Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas. | +13.6% | -37.5% | +340.0% |
| Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones. | $121.2M | -29.7% | +11.5% |
| Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero. | +16.8% | -28.5% | +3.8% |
| Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro. | 83.2% | -6.4% | +1.0% |
| Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico. | 4.02x | +30.8% | -37.8% |
| Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo. | $1.6B | +3.3% | +5.8% |
| Métrica | Anual (real vs estimado) | Sorpresa anual | Trimestral (real vs estimado) | Sorpresa trimestral |
|---|---|---|---|---|
| EPS Surprise | 2.03 vs 3.44 | -41.0% | 0.67 vs 0.62 | +8.0% |
| Revenue Surprise | $719.9M vs $725.6M | -0.8% | $183.9M vs $179.9M | +2.2% |
| Fecha | Ejecutivo | Cargo | Valor | Lado | Acciones | Precio |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Zhou Rong | officer: SENIOR EVP, PRODUCTION CENTER | Common Stock | D | 3,187 | $23.63 |
| Aug 11, 2026 | PRINS RICHARD K | director | Common Stock | D | 7,973 | $20.30 |
| Aug 7, 2026 | PETERS WILLIAM J | director, officer: CFO, EVP & TREASURER | Common Stock | A | 5,053 | $19.79 |
| Aug 7, 2026 | PETERS WILLIAM J | director, officer: CFO, EVP & TREASURER | Common Stock | D | 8,180 | $22.48 |
| Aug 7, 2026 | PETERS WILLIAM J | director, officer: CFO, EVP & TREASURER | Employee Stock Option (right to buy) | D | 5,053 | $19.79 |
Operator: Greetingsn and welcome to the Amphastar Pharmaceuticals, Inc. Second Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in the press release issued today and the presentation on the company's website. Please refer to our SEC filings, which can be found on the company's website and the SEC's website, for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliations to U.S. GAAP may be found in our earnings release. Please note this conference is being recorded. Our speakers today are Mr. Bill Peters, CFO; Mr. Dan Dischner, Senior Vice President of Corporate Communications; and Mr. Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations. I will now turn the conference over to your host, Mr. Dan Dischner, Senior Vice President of Corporate Communications. Dan, you may begin. Dan Dischner: Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar's Second Quarter 2026 Earnings Call. Earlier today, we reported the financial results for the second quarter ended June 30, 2026, which are available on the Investors page of our website. The second quarter was marked by strong execution across each of our strategic growth pillars. We observed continued demand across our commercial portfolio. We expanded our manufacturing capabilities and advanced both our development pipeline and regulatory programs. As a result, we generated improved financial performance during the second quarter. Revenue increased to approximately $184 million, reflecting both sequential and year-over-year growth. Profitability also improved significantly from the first quarter, driven by increased revenue, margin expansion, and enhanced operating performance. Despite a dynamic operating environment, our strategic priorities have remained consistent. We continue to focus on building a diversified pharmaceutical company supported by 3 complementary growth pillars. First, expanding and optimizing our branded and differentiated commercial portfolio. Second, advancing our pipeline of complex generic and biosimilar products. Third, progressing our proprietary development programs that have the potential to create significant long-term value. We believe this diversified business model provides multiple avenues for growth, enhances resilience, and reduces our dependence on any single product, market, or revenue stream. Turning to the first pillar of our growth strategy, expanding and optimizing our branded and differentiated commercial …
| Nombre | Cargo | Remuneración | Género | Año de nacimiento | Estado |
|---|---|---|---|---|---|
Yongfeng Zhang | Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director | USD 1,705,345 | — | 1947 | Active |
Ziping Luo | Chairman of the Board, Chief Scientist & Chief Operating Officer | USD 1,247,072 | — | 1950 | Active |
William J. Peters | Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director | USD 1,150,678 | Male | 1968 | Active |
Rong Zhou | Senior EVice President of Production & EVP of Scientific Affairs | USD 1,139,621 | Male | 1959 | Active |
Jacob Liawatidewi | Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director | USD 853,851 | Male | 1974 | Active |
Tony Marrs | Executive Vice President of Regulatory Affairs & Clinical Operations | — | — | — | Active |
Dan Dischner | Senior Vice President of Human Resources & Corporate Communication | — | Male | — | Active |
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
